– Abbott (ABT) and Sanofi partner to integrate to developing tools that combine the FreeStyle Libre technology with Sanofi′s insulin dosing information for future smartpens, insulin titration apps and cloud software.
– The integration will enable both people with diabetes and their doctors to make better-informed treatment decisions around medication, nutrition, and lifestyle.
Abbott (ABT) and Sanofi, today announced they are partnering to integrate glucose sensing and insulin delivery technologies that would help to further simplify how people with diabetes manage their condition. The two companies will take an innovative approach to connected care by developing tools that combine the revolutionary FreeStyle Libre technology with Sanofi′s insulin dosing information for future smart pens, insulin titration apps, and cloud software.
FreeStyle Libre System
Abbott’s FreeStyle Libre is a sensor-based glucose monitoring system used worldwide that reads glucose levels through a sensor that can be worn on the back of the upper arm eliminating the need for fingersticks. FreeStyle Libre has changed the lives of more than 1.5 million people across 46 countries, and has secured partial or full reimbursement in 33 countries, including Canada, France, Ireland, Japan, the United Kingdom, and the U.S.
Abbott, Sanofi Data-Sharing Details
The non-exclusive collaboration will initially enable data sharing, at the consent of the user, between Abbott′s FreeStyle Libre mobile app and cloud software and Sanofi′s connected insulin pens, apps and cloud software that are currently in development. This data sharing will enable both people with diabetes and their doctors to make better-informed treatment decisions around medication, nutrition, and lifestyle.
Availability & Timeline
Sanofi is currently working to provide connected pens, apps and cloud software that will be compatible with the FreeStyle Libre system and its compatible digital health tools. The two companies aim to bring this to people with diabetes within the next few years, pending local regulatory approvals.
Why It Matters
“For close to a century, Sanofi has been supporting those living with diabetes through our robust portfolio of medicines. This strategic relationship with Abbott is representative of the next evolution of our commitment for better diabetes care by incorporating digital tools into the daily life of people living with diabetes,” said Gustavo Pesquin, senior vice president of Global Diabetes and Cardiovascular Franchise at Sanofi. “By partnering with Abbott, we are a step closer to realizing our connected ecosystem, which would help improve control and the quality of life decision cycle for patients through individualized glycemic management of diabetes.”
